# C4 Therapeutics to Participate in Upcoming Conferences Canonical URL: https://biopharmsignal.com/news/CCCC/c4-therapeutics-to-participate-in-upcoming-conferences-10ae0b56 Ticker: CCCC Company: C4 Therapeutics Source: C4 Therapeutics Published: 2026-05-20 11:00 EST ## Summary C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to... ## Article Body C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences. TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Management will participate in a virtual fireside chat on May 26, 2026, at 2:30 pm ET. 2026 Jefferies Global Healthcare Conference Management will participate in a fireside chat on June 3, 2026, at 8:45 am ET, taking place in New York, New York. Goldman Sachs 47th Annual Global Healthcare Conference Management will participate in 1x1 meetings on June 10, 2026, taking place in Miami, FL. The live webcasts will be available on the Investors section of the company’s website at www.c4therapeutics.com . Archived replays of the webcasts will be available for approximately 90 days following the events. About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO ® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com . Contacts: Investors: Courtney Solberg Associate Director, Investor Relations CSolberg@c4therapeutics.com Leah Gibson Vice President, Investor Relations & Communications LGibson@c4therapeutics.com Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy LSpreen@c4therapeutics.com ## Recent Company News - 2026-06-11 11:00 EST — [C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population](https://biopharmsignal.com/news/CCCC/c4-therapeutics-presents-phase-1-data-at-european-hematology-association-eha-202-2551b658) — Source: C4 Therapeutics - 2026-05-20 11:00 EST — [C4 Therapeutics to Participate in Upcoming Conferences](https://biopharmsignal.com/news/CCCC/c4-therapeutics-to-participate-in-upcoming-conferences-10ae0b56) — Source: C4 Therapeutics - 2026-05-18 20:01 EST — [C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/CCCC/c4-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-70d8c55a) — Source: C4 Therapeutics - 2026-05-12 11:00 EST — [C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/CCCC/c4-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-dc6ffcc8) — Source: C4 Therapeutics - 2026-04-09 10:59 EST — [C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)](https://biopharmsignal.com/news/CCCC/c4-therapeutics-expands-long-term-partnership-with-roche-through-new-collaborati-b523cd96) — Source: C4 Therapeutics ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)